过敏性鼻炎血清VCAM-1和IL-6的表达及临床意义

目的探讨血管细胞黏附分子-1（VCAM-1）及白细胞介素-6（IL-6）在过敏性鼻炎发病中的作用及糖皮质激素治疗过敏性鼻炎的机制。方法选择过敏性鼻炎患者38：例，采用双抗体夹心酶联免疫吸附法（ELISA）测定患者经糖皮质激素全身和局部治疗前、后血清中VCAM-1和IL-6的含量变化，并与健康人比较，同时观察糖皮质激素对过敏性鼻炎的治疗效果。结果①过敏性鼻炎患者血清中VCAM-1和IL-6的含量高于正常对照组，两者比较，差异有显著性（P〈0．05）。②经糖皮质激素治疗后，过敏性鼻炎患者血清中VCAM-1和IL-6含量显著下降，下降的程度在两种疾病差异无显著性（P〉0.05）。③VCAM-1和IL-6血清含量在糖皮质激素治疗前、后比较，差异有显著性（P〈0．05）。④过敏性鼻，炎鼻腔组织VCAM-10IL-6之间经相关性分析，两者呈正相关（r=2．32，P〈0，05）。结论血管细胞黏附分子-1（VCAM-1）在过敏性鼻炎发生发展过程中起着重要作用。糖皮质激素可以通过抑制VCAM-1和IL-6对过敏性鼻炎起治疗作用，血清中VCAM-1和IL-6的水平变化可作为药物治疗这敏性鼻炎的临床判断指标。

Serum Levels and Clinical Values of Vascular Cell Adhesion Molecule-1 and IL-6 in Patients with Allergic Rhinitis

Objective To assess the role of vascular cell adhesion molecule-1 and IL-6 in etiology of allergic rhinitis. Methods The expression of sVCAM-1 and IL-6 in 35 patients with allergic rhinitis and 35 patients and 20 normal adults men were detected by sandwich enzyme-linked immunolorbent assay （ ELISA ）. All patients were treated by glucoeortieoid,serum VCAM-1 and IL-6 was detected post-treatment again. Results （1）Serum levels of VCAM-1 and IL- 6 in patients with allergic rhinitis were higher than that of control group ; there was significant difference between patients and contronl group. （2）Serum levels of VCAM-1 and IL-6 in patients were decreased after glucocorticoid treatment,there was not significant difference between VCAM-1 and IL-6. （3）There was significant difference between pre-treatment and post-treatment by glucocorticoid about serum contents of VCAM-1 and IL-6. （4）There are positive relevance tendency between VCAM-I and IL-6 in the nasal polyp of inflammatory mucosa and allergic rhinitis （ r = 2.32, P 〈 0.05 ）. Conclusions The elevated expressions of VCAM-I and IL-6 play an important role in patients with allergic rhinitis and nasal polyps. The VCAM-1 and IL-6 are down-regulated by systematic and topical glucocortieoid treatment and the decrease of sVCAM-1 and IL-6 are correlated with clinical effect.